Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 3, 2010, Pages 889-895

  Debeb, Bisrat G ^a   Xu, Wei ^a   Mok, Henry ^a   Li, Li ^a   Robertson, Fredika ^a   Ueno, Naoto T ^a   Reuben, Jim ^a   Lucci, Anthony ^a   Cristofanilli, Massimo ^a   Woodward, Wendy A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer stem progenitors cells; Mammospheres; Radiation; Three dimensional culture; Valproic acid

Indexed keywords

BREAST CANCER; BREAST CANCER STEM/PROGENITORS CELLS; MAMMOSPHERES; THREE-DIMENSIONAL CULTURE; VALPROIC ACID;

ACIDS; CELL CULTURE; MONOLAYERS; RADIOTHERAPY; THREE DIMENSIONAL; TRANSCRIPTION FACTORS;

STEM CELLS;

OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; VALPROIC ACID;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROTECTION; CELL RENEWAL; CELL STRAIN MCF 7; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIOSENSITIVITY; RADIOSENSITIZATION; THREE DIMENSIONAL MAMMOSPHERE;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; SOXB1 TRANSCRIPTION FACTORS; SPHEROIDS, CELLULAR; TUMOR STEM CELL ASSAY; VALPROIC ACID;

EID: 76049086450     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.09.052     Document Type: Article

References (43)

1. Woodward W.A., Chen M.S., Behbod F., et al. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104 (2007) 618-623
2. Phillips T.M., McBride W.H., and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98 (2006) 1777-1785
3. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458 (2009) 780-783
4. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
5. Chiou S.H., Kao C.L., Chen Y.W., et al. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS ONE 3 (2008) e2090
6. Meunier H., Carraz G., Neunier Y., et al. [Pharmacodynamic properties of N-dipropylacetic acid.]. Therapie 18 (1963) 435-438
7. Friedmann I., Atmaca A., Chow K.U., et al. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18 (2006) 415-420
8. Thelen P., Schweyer S., Hemmerlein B., et al. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24 (2004) 25-31
9. Olsen C.M., Meussen-Elholm E.T., Roste L.S., et al. Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. Mol Cell Endocrinol 213 (2004) 173-179
10. Gottlicher M., Minucci S., Zhu P., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
11. Phiel C.J., Zhang F., Huang E.Y., et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276 (2001) 36734-36741
12. Gurvich N., Tsygankova O.M., Meinkoth J.L., et al. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64 (2004) 1079-1086
13. Camphausen K., Cerna D., Scott T., et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114 (2005) 380-386
14. Chinnaiyan P., Cerna D., Burgan W.E., et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14 (2008) 5410-5415
15. Karagiannis T.C., Kn H., and El-Osta A. The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 1 (2006) 131-137
16. Bug G., Gul H., Schwarz K., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 65 (2005) 2537-2541
17. De Felice L., Tatarelli C., Mascolo M.G., et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 65 (2005) 1505-1513
18. Dontu G., Abdallah W.M., Foley J.M., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17 (2003) 1253-1270
19. Fillmore C.M., and Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10 (2008) R25
20. Mani S.A., Guo W., Liao M.J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008) 704-715
21. Gupta P.B., Onder T.T., Jiang G., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138 (2009) 645-659
22. Braun K.M., Niemann C., Jensen U.B., et al. Manipulation of stem cell proliferation and lineage commitment: Visualisation of label-retaining cells in wholemounts of mouse epidermis. Development 130 (2003) 5241-5255
23. Dey D., Saxena M., Paranjape A.N., et al. Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS ONE 4 (2009) e5329
24. Boyer L.A., Lee T.I., Cole M.F., et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122 (2005) 947-956
25. Loh Y.H., Wu Q., Chew J.L., et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 38 (2006) 431-440
26. Brown S.L., Kolozsvary A., Liu J., et al. Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat Res 169 (2008) 474-478
27. Huangfu D., Maehr R., Guo W., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26 (2008) 795-797
28. Botrugno O.A., Santoro F., and Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 280 (2009) 134-144
29. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: Can we see the forest for the trees?. Cell Mol Life Sci 64 (2007) 2090-2103
30. Beckers T., Burkhardt C., Wieland H., et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121 (2007) 1138-1148
31. Munster P.N., Troso-Sandoval T., Rosen N., et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61 (2001) 8492-8497
32. Zhou Q., Melkoumian Z.K., Lucktong A., et al. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 275 (2000) 35256-35263
33. Kuendgen A., Schmid M., Schlenk R., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106 (2006) 112-119
34. Cimino G., Lo-Coco F., Fenu S., et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66 (2006) 8903-8911
35. Jain N., Rossi A., and Garcia-Manero G. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol 41 (2009) 72-80
36. Bug G., Schwarz K., Schoch C., et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 92 (2007) 542-545
37. Fiskus W., Pranpat M., Balasis M., et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 5 (2006) 3096-3104
38. Woodward W.A., and Bristow R.G. Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol 19 (2009) 87-95
39. Baumann M., Krause M., and Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8 (2008) 545-554
40. Baumann M., Krause M., Thames H., et al. Cancer stem cells and radiotherapy. Int J Radiat Biol 85 (2009) 391-402
41. Cordes N., Seidler J., Durzok R., et al. Beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 25 (2006) 1378-1390
42. Sandfort V., Koch U., and Cordes N. Cell adhesion-mediated radioresistance revisited. Int J Radiat Biol 83 (2007) 727-732
43. Olive P.L., and Durand R.E. Drug and radiation resistance in spheroids: Cell contact and kinetics. Cancer Metastasis Rev 13 (1994) 121-138